Humoral Immunity to Measles, Mumps, Rubella, Diphtheria, Tetanus and Pertussis After Cancer Treatment in Children

IF 1.5 Q4 ONCOLOGY

Cancer reports Pub Date : 2025-05-19 DOI:10.1002/cnr2.70155

Susanna Sundell, Miia Laine, Liisa Järvelä, Ville Peltola, Tytti Vuorinen, Päivi Lähteenmäki, Linnea Schuez-Havupalo

{"title":"Humoral Immunity to Measles, Mumps, Rubella, Diphtheria, Tetanus and Pertussis After Cancer Treatment in Children","authors":"Susanna Sundell, Miia Laine, Liisa Järvelä, Ville Peltola, Tytti Vuorinen, Päivi Lähteenmäki, Linnea Schuez-Havupalo","doi":"10.1002/cnr2.70155","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Treatment for pediatric malignancies has distinct effects on the immune system.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>Our aim was to measure humoral immunity to measles, mumps and rubella (MMR), and diphtheria, tetanus and acellular pertussis (DTaP) vaccines after pediatric cancer treatment.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>We assessed IgG titers of 52 children against the vaccine antigens post-treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>After completed primary vaccination series for MMR and DTaP before treatment, post-treatment there was a considerable proportion of patients with below-reference titers against pertussis, diphtheria and tetanus, but only few subjects showed below-reference titers against measles, mumps and rubella. Our findings may have implications when considering re-vaccination policies.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70155","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Treatment for pediatric malignancies has distinct effects on the immune system.

Aims

Our aim was to measure humoral immunity to measles, mumps and rubella (MMR), and diphtheria, tetanus and acellular pertussis (DTaP) vaccines after pediatric cancer treatment.

Method

We assessed IgG titers of 52 children against the vaccine antigens post-treatment.

Results

After completed primary vaccination series for MMR and DTaP before treatment, post-treatment there was a considerable proportion of patients with below-reference titers against pertussis, diphtheria and tetanus, but only few subjects showed below-reference titers against measles, mumps and rubella. Our findings may have implications when considering re-vaccination policies.

查看原文本刊更多论文

儿童癌症治疗后对麻疹、腮腺炎、风疹、白喉、破伤风和百日咳的体液免疫

背景：小儿恶性肿瘤的治疗对免疫系统有明显的影响。我们的目的是测量儿童癌症治疗后对麻疹、腮腺炎和风疹（MMR）以及白喉、破伤风和无细胞百日咳（DTaP）疫苗的体液免疫。方法对52例儿童进行疫苗抗原免疫后IgG滴度测定。结果治疗前完成MMR和DTaP一次接种系列后，治疗后有相当比例的患者百日咳、白喉和破伤风的滴度低于参考值，但只有少数患者麻疹、腮腺炎和风疹的滴度低于参考值。我们的研究结果可能对考虑重新接种疫苗政策有所启示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊